Therapeutic Potential of Hydroxycinnamic Acid in Neurological Disorders: Mechanisms, Pharmacological Activities, and Clinical Perspectives
Background : Modern lifestyle, environment, and dietary patterns are heavily misaligned with our body’s actual needs, leading to a widespread global increase in severe mental health issues. According to the WHO, 1 in 7 people worldwide (over one billion as of 2021) live with a mental disorder, which significantly reduces life expectancy; for example, individuals with bipolar disorder die 13 years earlier on average. Improving dietary practices by including grains, fruits, vegetables, nuts, and seeds is imperative. These foods are rich in dietary fibre and polyphenols. Hydroxycinnamic acids (HCAs), a subclass of phenolic acids, offer wide-ranging pharmacological and therapeutic effects. However, compared with other polyphenols such as anthocyanins, there is a distinct gap in knowledge regarding the bioavailability and bioefficacy of HCAs. Aim : To examine how hydroxycinnamic acids (HCAs) affect neuroprotection and various aspects of therapeutic applications. Methods : A comprehensive review was conducted focusing on the bioavailability, mechanisms of action, and biological activities of the dominant HCAs, including caffeic, ferulic, and sinapic acids. Results : HCAs have several pharmacological and therapeutic effects. They mitigate neurodegeneration by regulating neuroinflammation, maintaining redox homeostasis, and preventing amyloid plaque aggregation. Conclusion : HCAs hold significant therapeutic promise for neurological disorders, though understanding of their bioavailability remains limited. Major Findings : HCAs exhibit significant neuroprotective effects through modulation of neuro-inflammatory signalling, maintenance of mitochondrial function, and prevention of protein aggregation. However, poor bioavailability and rapid metabolism remain major barriers to their clinical translation.